The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | The GEM-OPTIMAL study: an observational study using ALCYONE-optimized real-world evidence data
In this interview, Luis Esteban Tamariz‑Amador, MD, University Clinic of Navarra, Pamplona, Spain, discusses the findings of the GEM-OPTIMAL study. This prospective, observational study aimed to evaluate a treatment regimen of maintenance with bortezomib plus daratumumab (V-Dara) after induction with bortezomib, melphalan, prednisone plus daratumumab (VMP-Dara) in newly diagnosed transplant-ineligible patients with multiple myeloma (MM). This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
